IL2 and non-small cell lung carcinoma: A pilot (Kokowski et al., 2019) and clinical phase I study (Krause et al., 2004) demonstrated excellent safety profiles of autologous, ex vivo TKD/IL-2-activated NK cells, and patients with advanced NSCLC showed promising clinical responses in a randomized clinical phase II trial after adoptive transfer of ex vivo TKD/IL-2-activated NK cells (Multhoff et al., 2020).